Safe Administration of An Anti-PD-1 Antibody to Kidney-transplant Patients: 2 Clinical Cases and Review of the Literature.
- Julia K Winkler,
- Ralf Gutzmer,
- Carolin Bender,
- Nina Lang,
- Martin Zeier,
- Alexander H Enk,
- Jessica C Hassel
J Immunother 2017 Nov/Dec;40(9):341-344
*Department of Dermatology and National Center for Tumor Diseases (NCT) ‡Department of Nephrology, University Hospital Heidelberg, Heidelberg †Department of Dermatology and Allergy, Hannover Medical School, Skin Cancer Center, Hannover, Germany.
Antiprogrammed cell-death protein 1 (PD-1) antibodies have revolutionized therapy of metastatic melanoma and other tumors, but some subgroups of patients such as immunosuppressed patients after solid-organ transplantation, have regularly been excluded from clinical studies. We report 2 cases of kidney-transplant patients who received an anti-PD-1 antibody to treat metastatic melanoma. Treatment was tolerated well with no relevant adverse events and stable kidney functions, but the melanoma progressed in both patients. Read More